How often do skin pigmentation changes occur with nivolumab?
Skin pigmentation changes, such as vitiligo-like depigmentation or hyperpigmentation, occur in 1-7% of nivolumab-treated patients across clinical trials and real-world data. These are most common in melanoma patients, where vitiligo appears in up to 8-15% of cases due to the drug's immune activation against melanocytes.[1][2]
What do these skin changes look like?
Changes often manifest as:
- Patches of lightened skin (hypopigmentation or vitiligo), especially on the face, hands, and body.
- Darkened spots (hyperpigmentation) or generalized tanning.
- Onset typically within 3-6 months of starting treatment, sometimes persisting after discontinuation.[3]
Why does nivolumab cause this?
Nivolumab, a PD-1 inhibitor, boosts T-cell activity against tumors but can trigger autoimmune reactions targeting pigment-producing melanocytes. This is more frequent in skin cancer patients, where it correlates with better response rates—vitiligo signals stronger antitumor immunity.[1][4]
Are they a sign of nivolumab working?
Yes, in melanoma trials, skin depigmentation predicts improved progression-free survival. A meta-analysis of 2,000+ patients showed vitiligo patients had 50-70% lower risk of progression compared to those without.[2][5]
How are they managed?
Most cases need no treatment and are monitored. Options include:
- Topical steroids or calcineurin inhibitors for symptomatic areas.
- Sunscreen to prevent UV damage in depigmented skin.
- Rarely, nivolumab dose adjustment or pause if severe.3
Do they go away after stopping nivolumab?
Partial or full reversal happens in 30-50% of cases within 1-2 years post-treatment, but some persist indefinitely, especially vitiligo.[1][4]
How common compared to other immunotherapy side effects?
Less frequent than rash (20-40%), pruritus (10-20%), or fatigue, but more specific to anti-PD-1 drugs like nivolumab than CTLA-4 inhibitors. Combination with ipilimumab increases incidence to 10-20%.6
[1]: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5576179/
[2]: https://pubmed.ncbi.nlm.nih.gov/31237547/
[3]: Opdivo (nivolumab) prescribing information, Bristol Myers Squibb, 2023
[4]: https://www.nejm.org/doi/full/10.1056/NEJMoa1504627
[5]: https://pubmed.ncbi.nlm.nih.gov/28932928/